Beyond AI trades, a growth ace! Eli Lilly (LLY.US) weight-loss drug ramp-up and new product relay, JPMorgan raises target price to $1,650

Zhitong Finance APP has learned that JPMorgan is further raising its expectations for Eli Lilly's (LLY.US) earnings growth over the coming years. The research team led by analyst Chris Schott reiterated Eli Lilly's "Overweight" rating and the bank's "top pick" status, raising its December 2027 price target from $1,500 to $1,650, which still implies about 20.1% upside from the October 29 closing price of $1,373.70. The bank is bullish not only on the strong growth in current weight-loss drug sales, but also on the long-term growth potential brought by overseas market expansion, rising obesity treatment penetration in the United States, and the succession of new oral products. As the AI capital expenditure cycle prompts the market to re-examine tech stock valuations and earnings delivery capability, Eli Lilly is becoming another growth theme drawing Wall Street attention.